

New Jersey Drug Utilization Review Board
Virtual Platform
January 28, 2026

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of meeting transcript for October 22, 2025, meeting
https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/1-2026/DURB_Transcript_October_2025.pdf
- IV. Review of draft meeting summary for October 22, 2025, meeting (pages 4-7)
- V. Secretary's report (page 8)
- VI. Old Business
 - A. Fee-for-Service (FFS) and Managed Care Organization (MCO) Utilization Trends of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors (pages 9-10)
 - B. FFS and MCO Utilization Trends of Glucagon-like peptide-1 (GLP-1) Receptor Agonist and GLP-1/Glucose-dependent Insulinotropic Polypeptide (GIP) Agonists for Diabetes Mellitus (pages 11-12)
- VII. New Business
 - A. Proposed Protocol for Opzelura® (pages 13-15)
 - B. Proposed Addendum to Protocol for Duchenne Muscular Dystrophy Products (pages 16-19)
 - C. Proposed Addendum to Protocol for Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Modifiers (pages 20-25)

VIII. A. Informational Highlights/Reports

1. Gainwell Technologies/NJ MCO 3rd Quarter 2025 Prior Authorization Report (page 26-27)
2. Summary of DURB Action Items (pages 28-34)
3. DHS/DOH Pharmacy Programs Top Drugs Report/Physicians Administered Drugs Report (by amount paid and by category):

FFS top drugs:

https://www.nj.gov/humanservices/dmajs/boards/durb/agendas/1-2026/FFS_Top_Drugs_Report_November-2025.pdf

MCO top drugs:

https://www.nj.gov/humanservices/dmajs/boards/durb/agendas/1-2026/MCO_Top_Drugs_Report_October-2025.pdf

FFS top drugs by category:

https://www.nj.gov/humanservices/dmajs/boards/durb/agendas/1-2026/FFS_Top_Drugs_by_Category_November-2025.pdf

MCO top drugs by category:

https://www.nj.gov/humanservices/dmajs/boards/durb/agendas/1-2026/MCO_Top_Drugs_by_Category_October-2025.pdf

FFS antiviral drugs:

https://www.nj.gov/humanservices/dmajs/boards/durb/agendas/1-2026/FFS_Antiviral_Drugs_November-2025.pdf

B. Medication/Medical information

WHO issues global guideline on the use of GLP-1 medicines in treating obesity

<https://www.who.int/news-room/detail/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity>

One Dose versus Three Doses of Benzathine Penicillin G in Early Syphilis

<https://pubmed.ncbi.nlm.nih.gov/40902161/>

American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update

https://www.sciencedirect.com/science/article/pii/S1530891X25009772?ref=pdf_download&fr=RR-2&rr=9b086d0b5bb6fef2

Use of Risk Assessment to Guide Decision-Making for Blood Pressure Management in the Primary Prevention of Cardiovascular Disease: A Scientific Statement from The American Heart Association and American College of Cardiology

https://www.jacc.org/doi/10.1016/j.jacc.2025.08.001?_gl=1*11a97wk*_ga*MjAyNTIzNzYwMC4xNzU2ODMxNTQx*_ga_2V8VW4Y237*czE3NTY4MzE1NDAkbzEkZzAkdDE3NTY4MzE1NDAkjYwJGwwJGgw

RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons

<https://pubmed.ncbi.nlm.nih.gov/40884491/>

HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy

<https://www.hhs.gov/press-room/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy.html>

FDA asks for removal of suicide warnings on GLP-1 drugs

<https://www.axios.com/2026/01/13/fda-wegovy-zepbound-suicide-warnings>